R Kiessling
Overview
Explore the profile of R Kiessling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
176
Citations
5048
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Miyan M, Schmidt-Mende J, Kiessling R, Poschke I, de Boniface J
J Transl Med
. 2016 Jul;
14(1):227.
PMID: 27473163
Background: Molecular subtypes of breast cancer and presence of tumor-infiltrating immune cells have both been implicated as important predictive and prognostic factors for improved risk stratification and treatment individualization of...
2.
Ligtenberg M, Witt K, Galvez-Cancino F, Sette A, Lundqvist A, Lladser A, et al.
Oncoimmunology
. 2016 Jul;
5(5):e1128613.
PMID: 27467944
Metastatic melanoma is a fatal disease that responds poorly to classical treatments but can be targeted by T cell-based immunotherapy. Cancer vaccines have the potential to generate long-lasting cytotoxic CD8(+)...
3.
Mao Y, Poschke I, Kiessling R
J Intern Med
. 2014 Mar;
276(2):154-70.
PMID: 24597954
Tumour-induced immune dysfunction is a serious challenge to immunotherapy for cancer, and intact adaptive and innate cellular immunity is key to its success. Myelomonocytic cells have a central role in...
4.
Kono K, Mimura K, Kiessling R
Cell Death Dis
. 2013 Jun;
4:e688.
PMID: 23788045
Chemoradiotherapy can induce immunogenic cell death, triggering danger signals such as high-mobility group box 1 protein, and resulting in T-cell immunity. This concept can potentially be harnessed for clinical therapy...
5.
Poschke I, de Boniface J, Mao Y, Kiessling R
Int J Cancer
. 2011 Dec;
131(7):1611-20.
PMID: 22190148
Tumor-induced immune suppression has mainly been studied in patients with advanced cancer. Despite the fact that they are most likely to benefit from immunotherapy, patients with early stage cancers were...
6.
Poschke I, Mao Y, Adamson L, Salazar-Onfray F, Masucci G, Kiessling R
Cancer Immunol Immunother
. 2011 Nov;
61(6):827-38.
PMID: 22080405
Myeloid-derived suppressor cells (MDSC) are important regulators of the immune system and key players in tumor-induced suppression of T-cell responses. CD14+HLA-DR-/low MDSC have been detected in a great number of...
7.
de Boniface J, Poschke I, Mao Y, Kiessling R
Int J Cancer
. 2011 Aug;
131(1):129-39.
PMID: 21823123
Suppressive factors produced by tumors or tumor-associated cells represent a major obstacle to immune-mediated tumor eradication and immunotherapy. We studied tumor-dependent changes in expression of the ζ-chain, a key molecule...
8.
Klein G, Klein G, Karre K, Kiessling R
Immunogenetics
. 2011 Feb;
7(1):391-404.
PMID: 21302094
A spectrum of lymphomas, sarcomas, and carcinomas were tested for F(1) hybrid resistance after s.c. inoculation of small numbers of cells into syngeneic and F(1) hybrid mice. Significant F(1) resistance...
9.
Copier J, Dalgleish A, Britten C, Finke L, Gaudernack G, Gnjatic S, et al.
Eur J Cancer
. 2009 Jan;
45(8):1424-31.
PMID: 19167214
A series of cancer vaccines have been evaluated in clinical trials with encouraging results, but the demonstration of clinical benefit in confirmatory studies has so far proven to be difficult....
10.
Kiessling R, De Geer A, Johansson C, Poschke I, Triulzi C, Vertuani S
Cancer Immunol Immunother
. 2007 Nov;
57(4):593-9.
PMID: 18026952
No abstract available.